Targeting RNA in Disease with Novel Technologies (TRDNT) Challenge – Phase II: Stage I supports teams and organizations developing RNA-targeting prototypes to enable precision therapies for human disease.
Funder: NIH Challenges
Due Dates: December 1, 2026 (Stage I submissions open) | February 1, 2027, 11:59 PM Eastern Time (Stage I submissions close)
Funding Amounts: $120,000 per winner, up to 25 winners; $3 million Stage I prize purse
Summary: Supports early prototype development, disease-relevant validation planning, and public dissemination planning for novel technologies targeting endogenous RNA.
Key Information: Phase I participation is not required; only solutions targeting endogenous RNA to treat disease are competitive.
The Targeting RNA in Disease with Novel Technologies (TRDNT) Challenge is an NIH Common Fund Venture Program prize competition supporting the development, validation, and dissemination of publicly available RNA-targeting technologies. It aims to enable precision therapies for diseases caused by difficult-to-drug proteins that could be addressed upstream at the RNA level, or currently incurable diseases rooted in RNA dysfunction.
Phase II: Stage I rewards interim progress toward a functional prototype, initial performance testing, and a viable human disease use case. Competitive technologies should address multiple diseases and unmet medical needs through novel approaches rather than well-established methods. Examples include modifying RNA–protein interactions, targeting long non-coding RNAs, developing RNA-targeting small-molecule screening libraries, and modifying aberrant RNA structures. Early planning for public access and dissemination is central to this stage.